Is metformin safe and appropriate for use in pregnancy in a woman with pre‑existing type 2 diabetes or gestational diabetes not controlled by diet and exercise, and what are the recommended dosing and contraindications?

Metformin in Pregnancy

Direct Recommendation

Insulin is the preferred and first-line agent for managing both gestational diabetes mellitus (GDM) and pre-existing type 2 diabetes in pregnancy; metformin should not be used as first-line therapy because it crosses the placenta and raises concerns about long-term offspring metabolic health. 1, 2

---

Clinical Decision Algorithm

For Gestational Diabetes Mellitus (GDM)

First-line approach:

• Begin with lifestyle modification (medical nutrition therapy and exercise), which controls GDM in 70-85% of women 1
• If glycemic targets are not met, add insulin as the preferred pharmacologic agent 1

When metformin may be considered (second-line only):

• Only when insulin cannot be used safely or effectively due to specific barriers: cost, language barriers, comprehension issues, or cultural factors that prevent insulin acceptance 1, 2
• Critical contraindications to metformin: Do not use if the patient has hypertension, preeclampsia, risk of intrauterine growth restriction, or suspected placental insufficiency 1, 2

Key efficacy limitation:

• Metformin fails to achieve adequate glycemic control in 25-28% of GDM patients, requiring supplemental insulin 1

For Pre-existing Type 2 Diabetes

Definitive recommendation:

• Continue insulin throughout pregnancy as the preferred agent 1, 2
• Do not switch from insulin to metformin simply because the patient prefers oral medication 2

Metformin as adjunct:

• One RCT showed that adding metformin to insulin in type 2 diabetes reduced maternal weight gain and cesarean births but doubled the rate of small-for-gestational-age neonates 1
• This risk-benefit profile makes insulin monotherapy preferable 1, 2

For Type 1 Diabetes

• Insulin is mandatory; metformin is not a treatment option 2

---

Critical Safety Concerns About Metformin

Placental Transfer

• Metformin crosses the placenta freely, resulting in umbilical cord blood levels equal to or higher than maternal levels 1, 2, 3
• In contrast, insulin does not cross the placenta to any measurable extent 1

Long-term Offspring Metabolic Effects (Most Concerning Evidence)

Follow-up studies at 7-10 years:

• Children exposed to metformin in utero had significantly higher BMI, waist-to-height ratios, and waist circumferences compared to insulin-exposed children 1, 2
• The MiG TOFU study showed 9-year-old offspring in the Auckland cohort were heavier with increased central adiposity 1

Meta-analysis findings:

• Metformin exposure results in smaller neonates at birth with accelerated postnatal growth, leading to higher childhood BMI 1, 2
• This pattern of growth restriction followed by catch-up growth is metabolically unfavorable 1

PCOS studies:

• Follow-up of 4-10 year old children whose mothers used metformin for PCOS showed higher BMI, increased obesity rates, and borderline increased fat mass 1

Short-term Neonatal Concerns

• Reduced risk of neonatal hypoglycemia compared to insulin 1
• Potential for small-for-gestational-age births, especially in women with type 2 diabetes and comorbidities 1, 4

---

Specific Clinical Scenarios

Polycystic Ovary Syndrome (PCOS)

• If metformin was used to induce ovulation, discontinue it by the end of the first trimester once pregnancy is confirmed 1, 2, 5
• Metformin does not reduce the risk of gestational diabetes in high-risk women with PCOS 1, 2

Glycemic Targets During Pregnancy

When using any agent, aim for: 1

• Fasting <95 mg/dL (5.3 mmol/L)
• One-hour postprandial <140 mg/dL (7.8 mmol/L) OR
• Two-hour postprandial <120 mg/dL (6.7 mmol/L)

---

Common Pitfalls to Avoid

1. Do not use metformin as first-line therapy simply because it is oral, less expensive, or more convenient than insulin 1, 2

2. Do not continue metformin in women with hypertensive disorders or at risk for placental insufficiency due to potential for growth restriction or acidosis 1, 2

3. Do not assume metformin will prevent GDM in high-risk women—meta-analyses show it does not reduce GDM risk 1, 2

4. Do not overlook treatment failure rates—14-46% of patients on metformin require supplemental insulin 2, 5

5. Do not forget to counsel about long-term offspring effects when metformin is being considered, as the metabolic consequences in childhood are concerning 1, 2

---

Guideline Consensus Position

The American Diabetes Association guidelines from 2019,2022, and 2023 consistently state that insulin is the first-line and preferred agent for both GDM and type 2 diabetes in pregnancy 1. Metformin and glyburide should not be used as first-line agents because they cross the placenta and lack long-term safety data for offspring 1. The FDA label confirms limited data in pregnancy and notes that metformin crosses the placental barrier 3.

---

When Metformin Might Be Acceptable (Rare Circumstances)

Only consider metformin when:

• Insulin cannot be used due to insurmountable barriers (cost, language, comprehension, cultural factors) 1, 2
• The patient does NOT have hypertension, preeclampsia, or risk factors for intrauterine growth restriction 1, 2
• The patient is fully counseled about placental transfer and concerning long-term offspring metabolic data 1, 2
• Close monitoring is in place for treatment failure requiring insulin supplementation 2, 5

Documented benefits if metformin is used:

• Less maternal weight gain compared to insulin 1, 4
• Lower rates of neonatal hypoglycemia 1
• Potentially fewer large-for-gestational-age births 4
• Greater patient acceptability than insulin 6